Informations générales
330781329
8610Z
Association Loi 1901 Reconnue d'Utilité Publique
33
Adresse
| 229 CRS DE L'ARGONNE 33076 BORDEAUX CEDEX | Accès au plan |
Listes des essais cliniques en recrutement
| Etude | Statut | Dernière mise à jour | |
|---|---|---|---|
| NCT04055220 | A Randomized, Placebo-controlled, Double-blinded, Multicentre Study Evaluating the Efficacy and Safety of Regorafenib as Maintenance Therapy After First-line Treatment in Patients With Bone Sarcomas (REGOSTA) | 09 août 2023 | |
| NCT03624244 | Randomized Comparative Prospective Multicentre Phase II Trial Evaluating Clinical Impact of Interruption VS Maintenance of AI in Patients with Locally Advanced/ Metastatic LGESS (BFR-ESS) | 20 mars 2023 | |
| NCT04258137 | Circulating DNA to Improve Outcome of Oncology PatiEnt: A Randomized Study - COPE Study (COPE) | 20 mars 2023 | |
| NCT04008238 | Prospective Identification of Predictive Biomarkers of Trabectedin Efficacy in Non-L Soft-tissue Sarcoma Patients (PIPER) | 20 mars 2023 | |
| NCT03915678 | Atezolizumab Combined With BDB001 AnD Immunogenic Radiotherapy in Patients With Advanced Solid Tumors (AGADIR) | 20 mars 2023 | |
| NCT03805022 | Phase III Trial Investigating the Potential Benefit of Intensified Peri-operative Chemotherapy With in High-risk CINSARC Patients With Resectable Soft-tissue SARComas (CIRSARC) | 20 mars 2023 | |
| NCT03275311 | Epidemiological Strategy and Medical Economic (ESME) Research Program / Academic Real World Database: Evolution of the Therapeutic Care in Metastatic Breast Cancer Across the French Comprehensive Cancer Centers From 2008 (ESME-MBC) | 20 mars 2023 | |
| NCT02789384 | Prognostic Value of the CINSARC (Complexity Index in Sarcoma) Signature and Correlation With Chemotherapy Efficacy in Soft-tissue Sarcomas. A Biomarker Study. (NEOSarcomics ) (NEOSarcomics) | 20 mars 2023 | |
| NCT02630368 | A Phase I/II Study of Metronomic Cyclophosphamide and Oncolytic Poxvirus JX-594 in Patients With Advanced Hormone-receptor Positive and Triple Negative Breast Cancer and Advanced Soft Tissue Sarcoma (METROmaJX) (METROmaJX) | 20 mars 2023 | |
| NCT02534649 | Bergonie Institut Profiling : Fighting Cancer by Matching Molecular Alterations and Drugs in Early Phase Trials (BIP) | 20 mars 2023 | |
| NCT04428554 | Consolidative Radiotherapy for Metastatic Urothelial Bladder Cancer Patients Without Progression and With no More Than Three Residual Metastatic Lesions Following First Line Systemic Therapy: a Prospective Randomized Comparative Phase II Trial (BLAD-RAD01) | 20 mars 2023 | |
| NCT03848052 | Epidemiological Strategy and Medical Economic (ESME) Research Program / Academic Real World Data Platform: Evolution of the Therapeutic Care in Lung Cancer in France Since 2015 | 05 novembre 2022 | |
| NCT02819362 | Benefit of a Diagnostic MRI in Case of Pathological Nipple Discharge With Normal Mammography / Ultrasound. | 05 novembre 2022 | |
| NCT00964171 | A Phase II Trial to Assess the Efficacy of Efavirenz as Second-line Monotherapy for the Treatment of Advanced Pancreatic Adenocarcinomas. | 29 octobre 2022 |
Listes des établissements rattachés
| Finess | Etablissement | Catégorie | Adress |
|---|---|---|---|
| 330000662 | INSTITUT BERGONIE | Centre de Lutte Contre Cancer | 229 CRS DE L'ARGONNE 33076 BORDEAUX CEDEX |